Design, synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl)-2-hydroxy-propyl]-3,3-diphenylpyrrolidin-2-one derivatives with antiarrhythmic, antihypertensive, and α-adrenolytic activity
synthesized and evaluated for their binding affinity for α1- and α2-adrenoceptors (ARs), as well as their antiarrhythmic, and antihypertensive activities. The highest affinity for the α1-AR was displayed by 1-3-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-2-hydroxy-propyl}-3,3-diphenylpyrrolidin-2-one (7), which binds with a pKi = 7.28. The highest affinity for the α2-AR was shown by 1-3-[4-(2-methoxy-ph